Diamandis
Argiris Diamandis, Athens GR
Patent application number | Description | Published |
---|---|---|
20100091109 | MACHINE-READABLE FORM CONFIGURATION AND SYSTEM AND METHOD FOR INTERPRETING AT LEAST ONE USER MARK - One embodiment of the present invention relates to a machine-readable form configuration (and associated method). Another embodiment of the present invention relates to a system for interpreting at least one user mark (and associated methods). In one example, a plurality of user marks may be interpreted. In another example, the machine-readable form may be a lottery play slip, survey, test, or the like. In another example, the system may interpret user mark(s) made on a lottery play slip, survey, test or the like. In another example, the system may interpret user mark(s) made on a paper or the like having non-planar distortion(s). | 04-15-2010 |
20130267297 | METHODS AND SYSTEMS FOR CONDUCTING LOTTERY GAMES WITH PORTABLE DEVICES ENABLED FOR NEAR FIELD COMMUNICATION (NFC) - In some embodiments, the instant invention provides for a computer system that includes a processor executing the code to: receive an indication indicating that a player desires to participate in a lottery game based on a near field communication (NFC) between a mobile device of the player and a first game piece associated with the lottery game conducted by a game conducting authority; conduct a drawing in accordance with rules of the lottery game; receive an indication identifying an action performed by the player in accordance with the rules of the lottery game where the action is based on: i) a result of the drawing and ii) NFC communication between the mobile device of the player and a second game piece associated with the lottery game; and distribute a prize to player in accordance with the rules of the lottery game. | 10-10-2013 |
20140055622 | MACHINE-READABLE FORM CONFIGURATION AND SYSTEM AND METHOD FOR INTERPRETING AT LEAST ONE USER MARK - One embodiment of the present invention relates to a machine-readable form configuration (and associated method). Another embodiment of the present invention relates to a system for interpreting at least one user mark (and associated methods). In one example, a plurality of user marks may be interpreted. In another example, the machine-readable form may be a lottery play slip, survey, test, or the like. In another example, the system may interpret user mark(s) made on a lottery play slip, survey, test or the like. In another example, the system may interpret user mark(s) made on a paper or the like having non-planar distortion(s). | 02-27-2014 |
20140206426 | METHODS AND SYSTEMS FOR CONDUCTING LOTTERY GAMES WITH PORTABLE DEVICES ENABLED FOR NEAR FIELD COMMUNICATION (NFC) - In some embodiments, the instant invention provides for a computer system that includes a processor executing the code to: receive an indication indicating that a player desires to participate in a lottery game based on a near field communication (NFC) between a mobile device of the player and a first game piece associated with the lottery game conducted by a game conducting authority; conduct a drawing in accordance with rules of the lottery game; receive an indication identifying an action performed by the player in accordance with the rules of the lottery game where the action is based on: i) a result of the drawing and ii) NFC communication between the mobile device of the player and a second game piece associated with the lottery game; and distribute a prize to player in accordance with the rules of the lottery game. | 07-24-2014 |
Eleftherios P. Diamandis, Toronto CA
Patent application number | Description | Published |
---|---|---|
20110151580 | METHOD FOR THE DETECTION OF BREAST CANCER BY DETERMINING ALCAM AND/OR BCAM LEVELS IN A PATIENT - The present application describes biomarkers and methods useful for screening for, diagnosing or detecting the presence and severity of breast cancer in a subject. The present application also provides methods for determining the prognosis of a subject with breast cancer as well as methods for monitoring the therapeutic response to a breast cancer treatment or therapy. | 06-23-2011 |
20110256560 | METHODS AND COMPOSITIONS FOR THE DETECTION OF OVARIAN CANCER - Provided is a method of screening for, diagnosing or detecting ovarian cancer in a subject comprising (a) determining a level of mdogen-2 in a test sample from the subject, and (b) comparing the level of mdogen-2 in the test sample with a control, where detecting an increase in the level of mdogen-2 in the test sample compared to the control is indicative of ovarian cancer in the subject. | 10-20-2011 |
20120178111 | METHODS AND COMPOSITIONS FOR THE DETECTION OF LUNG CANCERS - A method of screening for, diagnosing or detecting lung cancer in a subject, the method comprising: a) determining a level of a biomarker or a plurality of biomarkers in a sample from the subject, wherein the biomarker(s) is/are selected from the biomarkers listed in Table 8, and b) comparing the level of each biomarker in the sample with a control; wherein an increased level of any one of the biomarkers compared to the control is indicative that the subject has lung cancer Biomarkers were identified by shot-gun proteomics analysis of lung cancer cell-lines H1688, H520, H460 and H23. These lines are of differing histo-types, and were grown on serum-free media. | 07-12-2012 |
20120288873 | BIOMARKERS FOR THE DETECTION AND SCREENING OF DOWN SYNDROME - The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein. | 11-15-2012 |
20130210666 | Markers of the Male Urogenital Tract - Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers. | 08-15-2013 |
20150072349 | Cancer Biomarkers and Methods of Use - A method of evaluating a probability a subject has a cancer, diagnosing a cancer and/or monitoring cancer progression comprising: a. measuring an amount of a biomarker selected from the group consisting of CUZD1 and/or LAMC2 and/or the group CUZD1, LAMC2, AQP8, CELA2B, CELA3B, CTRB1, CTRB2, GCG, IAPP, INS, KLK1, PNLIPRP1, PNLIPRP2, PPY, PRSS3, REG3G, SLC30A8, KLK3, NPY, PSCA, RLN1, SLC45A3, DSP, GP73, DSG2, CEACAM7, CLCA1, GPA33, LEFTY1, ZG16, IRX5, LAMP3, MFAP4, SCGB1A1, SFTPC, TMEM100, NPY, PSCA, RLN1 and/or SLC45A3 in a test sample from a subject with cancer; wherein the cancer is pancreas cancer if CUZD1, LAMC2, AQP8, CELA2B, CELA3B, CTRB1, CTRB2, GCG, LAPP, INS, KLK1, PNLIPRP1, PNLIPRP2, PPY, PRSS3, REG3G, SLC30A8, DSP, GP73 and/or DSG2 is selected; the cancer is colon cancer if CEACAM7, CLCA1, GPA33, LEFTY1 and/or ZG16 is selected, the cancer is lung cancer if IRX5, LAMP3, MFAP4, SCGB1A1, SFTPC and/or TMEM100 is selected; or the cancer is prostate cancer if NPY, PSCA, RLN1 and/or SLC45A3 is selected; b. comparing the measured amount to a control and detecting an increase in the amount of the biomarker compared to control; and c. identifying the subject as having or having an increased probability of having the cancer when an increase in the biomarker compared to control is detected. | 03-12-2015 |
Peter H. Diamandis, Santa Monica, CA US
Patent application number | Description | Published |
---|---|---|
20080217472 | ROCKET-POWERED VEHICLE RACING REALITY SYSTEM - An aerial vehicle race and reality system for entertaining spectators wherein computer-generated images are optionally provided to at-least partially define a race-course. | 09-11-2008 |
20080217473 | ROCKET-POWERED VEHICLE RACING COMPETITION - A method for racing rocket-powered vehicles directly against one another is provided in which a first rocket-powered vehicle simultaneously races against a second rocket-powered vehicle to be the first to complete a race course. The method may include the first and second rocket-powered vehicles performing a pre-determined maneuver while proximate a group of spectators, and/or the rocket-powered vehicles strategically performing the steps of gliding and boosting the flight of their rocket-powered vehicle in accordance with a pre-determined maximum fuel criteria. The method further may include permitting spectator interaction with participants of the racing competition and enabling spectators to compete with actual participants via virtual vehicles. The method may also include the rocket-powered vehicles performing a refueling operation. The method may further include providing audible or visual identifiers of the vehicles. In addition, the method may include providing safety data to ensure safe separation between competing vehicles. | 09-11-2008 |
20080221745 | COLLECTION AND DISTRIBUTION SYSTEM - A collection and distribution system wherein information is collected from one or more aerial vehicles and from one or more ground-based sources before being processed and provided to an end-user. | 09-11-2008 |
20100096491 | ROCKET-POWERED ENTERTAINMENT VEHICLE - A rocket-powered vehicle used for entertainment, namely races, exhibitions, competitions, and revenue-generating events. | 04-22-2010 |
Phedias Diamandis, Toronto CA
Patent application number | Description | Published |
---|---|---|
20090076019 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE - A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and methods of using the modulators and compositions, in particular to treat neurological disorders (e.g. brain or CNS cancer) or damage are also disclosed. | 03-19-2009 |